In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

La Jolla acquires GliaMed’s regenerative immunophilin ligands; returns rights shortly after

Executive Summary

Cell reprogramming biotech GliaMed Inc. has sold its regenerative immunophilin ligand (RIL) program to La Jolla Pharmaceutical Co. (formerly focused on immune diseases). The deal includes patents and patent rights, know-how, regulatory registrations, raw materials, study drug supplies, and contractual rights.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Intra-Biotech Deal
    • Product Purchase
    • R&D and Marketing (Licensing)

Related Companies